262 related articles for article (PubMed ID: 27067321)
1. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
[TBL] [Abstract][Full Text] [Related]
6. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.
Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM
Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
9. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
10. Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.
Srinivasan P; Moss JA; Gunawardana M; Churchman SA; Yang F; Dinh CT; Mitchell JM; Zhang J; Fanter R; Miller CS; Butkyavichene I; McNicholl JM; Smith TJ; Baum MM; Smith JM
PLoS One; 2016; 11(6):e0157061. PubMed ID: 27275923
[TBL] [Abstract][Full Text] [Related]
11. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
[TBL] [Abstract][Full Text] [Related]
12. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
[TBL] [Abstract][Full Text] [Related]
13. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
Smith JM; Rastogi R; Teller RS; Srinivasan P; Mesquita PM; Nagaraja U; McNicholl JM; Hendry RM; Dinh CT; Martin A; Herold BC; Kiser PF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16145-50. PubMed ID: 24043812
[TBL] [Abstract][Full Text] [Related]
14. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
[TBL] [Abstract][Full Text] [Related]
15. Models for predicting effective HIV chemoprevention in women.
Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
[TBL] [Abstract][Full Text] [Related]
16. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
Ouattara LA; Thurman AR; Jacot TA; Cottrell M; Sykes C; Blake K; Fang X; Ju S; Vann NC; Schwartz J; Doncel GF
J Acquir Immune Defic Syndr; 2022 Jan; 89(1):87-97. PubMed ID: 34878438
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
[TBL] [Abstract][Full Text] [Related]
18. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
Malcolm RK; Veazey RS; Geer L; Lowry D; Fetherston SM; Murphy DJ; Boyd P; Major I; Shattock RJ; Klasse PJ; Doyle LA; Rasmussen KK; Goldman L; Ketas TJ; Moore JP
Antimicrob Agents Chemother; 2012 May; 56(5):2251-8. PubMed ID: 22330914
[TBL] [Abstract][Full Text] [Related]
19. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]